Skip Navigation

Publication Detail

Title: Sodium P-aminosalicylic Acid Inhibits Manganese-Induced Neuroinflammation in BV2 Microglial Cells via NLRP3-CASP1 Inflammasome Pathway.

Authors: Fang, Yuanyuan; Peng, Dongjie; Liang, Yuan; Lu, Lili; Li, Junyan; Zhao, Lin; Ou, Shiyan; Li, Shaojun; Aschner, Michael; Jiang, Yueming

Published In Biol Trace Elem Res, (2021 Sep)

Abstract: BACKGROUND: Sodium p-aminosalicylic acid (PAS-Na) was reported to exhibit anti-inflammatory effect in the nervous system. However, the mechanism by which PAS-Na exhibits anti-inflammatory effects on manganese (Mn)-stimulated BV2 microglia cells remains unclear. Thus, this study investigated the role of PAS-Na in Mn-stimulated BV2 microglial cells. METHODS: Microglia-like BV2 were treated with MnCl2 with or without the non-steroidal anti-inflammatory drug PAS-Na for 12 or 24 h to examine cell viability using MTT; for 24 or 48 h to examine levels of NLRP3, CASP1, IL-1β, and IL-18 mRNA using Real-Time quantitative PCR; for 48 h to examine levels of NLRP3 and CASP1 inflammasomes, measured by western blot analysis; and for 48 h to examine levels of inflammatory cytokines, measured by enzyme-linked immunosorbent assay. RESULTS: The MTT assay showed that PAS-Na produced significant neuroprotective effect by preventing Mn-induced inflammation in BV2 microglial cells. PAS-Na significantly concentration and time dependently inhibited Mn-induced production of NLRP3, CASP1, IL-1β, and IL-18. CONCLUSION: Taken together, our results suggest that PAS-Na exerts anti-inflammatory effects in Mn-stimulated BV2 microglial cells via downregulation of NLRP3, CASP1, IL-1β, and I L-18. Furthermore, a high concentration and prolonged PAS-Na treatment appear necessary for its therapeutic efficacy. Taken together, we conclude that PAS-Na affords therapeutic efficacy in mitigating neurological conditions associated with neuroinflammation.

PubMed ID: 33156491 Exiting the NIEHS site

MeSH Terms: Aminosalicylic Acid*; Inflammasomes; Manganese/toxicity; Microglia; NLR Family, Pyrin Domain-Containing 3 Protein; Pharmaceutical Preparations*; Sodium

Back
to Top
Last Reviewed: October 07, 2024